| Followers | 202 |
| Posts | 25627 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Thursday, April 01, 2021 3:21:52 AM
So is your argument that 1) they have not received buy in from all their relevant RA’s; or is it 2) that they proceeded without the buy in, despite saying that they would not, and never told us otherwise?
This description of the relevant statements and events seems accurate to me as per my best recollection, and quotes other posters here, and was created by another poster here. It seems like we have a number of people who recall similar circumstances and statements that are consistent with also the nature of the regulatory practice as we understand it with regard to a single, global trial. It is u likely that different agencies will have fundamentally different SAP’s and measures applying to the same trial. There may be some differences around the edges, but it seems unlikely that it would make sense for them to coordinate on such sorts of approvals and then, for the same exact trial, diverge in basic measures by jurisdiction, particularly given the many regulations they have put into place to avoid those kinds of conflicts and different standards.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160657769
This description of the relevant statements and events seems accurate to me as per my best recollection, and quotes other posters here, and was created by another poster here. It seems like we have a number of people who recall similar circumstances and statements that are consistent with also the nature of the regulatory practice as we understand it with regard to a single, global trial. It is u likely that different agencies will have fundamentally different SAP’s and measures applying to the same trial. There may be some differences around the edges, but it seems unlikely that it would make sense for them to coordinate on such sorts of approvals and then, for the same exact trial, diverge in basic measures by jurisdiction, particularly given the many regulations they have put into place to avoid those kinds of conflicts and different standards.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160657769
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
